AXSM Live-Signale | Maximieren Sie Profite mit Getagraph.com

KAUFEN 353 min ago

@ $74.00

Ausgestellt: 29 Apr 2024 @ 19:45

Rendite: -0.42%

Vorheriges Signal: Apr 26 - 17:43

Vorheriges Signal: Verkaufen

Rendite: 2.85 %

Live Chart Being Loaded With Signals

Commentary (29 Apr 2024 @ 22:00):

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States...

Stats
Tagesvolumen	498 467
Durchschnittsvolumen	721 738
Marktkapitalisierung	3.49B
EPS	$0 ( 2024-02-20 )
Nächstes Ertragsdatum	( $-1.210 ) 2024-05-06
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-13.98
ATR14	$2.13 (2.89%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-01	Jacobson Mark L.	Buy	24 662	Common Stock
2024-04-01	Jacobson Mark L.	Sell	24 662	Stock Option (Right to Buy)
2024-04-01	Jacobson Mark L.	Sell	24 662	Common Stock
2024-03-14	Jeffs Roger	Buy	16 976	Common Stock
2024-03-14	Jeffs Roger	Buy	13 000	Common Stock

INSIDER POWER
55.14
Last 99 transactions
Buy: 2 269 939 \| Sell: 680 650

Volumen Korrelation

Lang: -0.63 (weak negative)

Kurz: -0.86 (strong negative)

Signal:(44) Neutral

Axsome Therapeutics Inc Korrelation

10 Am meisten positiv korreliert
MMAC	0.888
BOCH	0.879
MIRM	0.876
RNEM	0.87
BATRA	0.869
SINO	0.866
BATRK	0.86
VIRI	0.858
LMRKO	0.854
RAM	0.851

10 Am meisten negativ korreliert
APOP	-0.937
RMRM	-0.915
TDAC	-0.893
MAGS	-0.891
CMLF	-0.868
BHTG	-0.861
VTRU	-0.848
GAINL	-0.847
TRIT	-0.845
SSTI	-0.836

Wussten Sie das?

Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).

Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.

Axsome Therapeutics Inc Korrelation - Währung/Rohstoff

0.19
( neutral )

-0.39
( neutral )

0.00
( neutral )

0.10
( neutral )

-0.73
( moderate negative )

-0.32
( neutral )

Axsome Therapeutics Inc Finanzdaten

Annual	2023
Umsatz:	$270.60M
Bruttogewinn:	$237.70M (87.84 %)
EPS:	$-5.27

FY	2023
Umsatz:	$270.60M
Bruttogewinn:	$237.70M (87.84 %)
EPS:	$-5.27

FY	2022
Umsatz:	$50.04M
Bruttogewinn:	$44.84M (89.61 %)
EPS:	$-4.86

FY	2021
Umsatz:	$0.00
Bruttogewinn:	$0.00 (0.00 %)
EPS:	$-3.47

Financial Reports:

No articles found.

Axsome Therapeutics Inc

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation. It is also developing AXS-07, a novel, oral, rapidly absorbed, multi-mechanistic, and investigational medicine that has completed two Phase III trials for the acute treatment of migraine; AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is in Phase III trial to treat narcolepsy; and AXS-14, a novel, oral, and investigational medicine that is in Phase III trial for the treatment of fibromyalgia. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.